D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 46.37 CNY 0.63% Market Closed
Market Cap: 19.3B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dizal Jiangsu Pharmaceutical Co Ltd
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Other Operating Expenses
ÂĄ31.6m
CAGR 3-Years
104%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Operating Expenses
ÂĄ210.1m
CAGR 3-Years
12%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Other Operating Expenses
ÂĄ6m
CAGR 3-Years
N/A
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Operating Expenses
ÂĄ45.2m
CAGR 3-Years
-7%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Operating Expenses
ÂĄ20m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Operating Expenses
-ÂĄ184.4m
CAGR 3-Years
N/A
CAGR 5-Years
-31%
CAGR 10-Years
-15%
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.9B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
29.84 CNY
Overvaluation 36%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Operating Expenses?
Other Operating Expenses
31.6m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Other Operating Expenses amounts to 31.6m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
-3%

Over the last year, the Other Operating Expenses growth was 343%. The average annual Other Operating Expenses growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 104% over the past three years , -3% over the past five years .

Back to Top